Semaglutide, tirzepatide and retatrutide are three incretin-related peptide analogues that are frequently compared because they sit along a progression from single- to multi-receptor activity. The single most important difference for a researcher is which receptors each compound engages. This guide compares their receptor profiles, structure, and development status, and clarifies how the reference compounds sold on ChainPep relate to the widely discussed prescription medicines. Everything here is for in-vitro research planning; it is not medical advice or an efficacy comparison.

Important distinction. Semaglutide and tirzepatide exist as approved prescription medicines under brand names; retatrutide has been in clinical development. ChainPep supplies lyophilized reference compounds for qualified laboratory research only — not these medicines, and not for human use.

Receptor profile at a glance

CompoundReceptor activityPathway characterization
SemaglutideGLP-1Long-acting single incretin agonist
TirzepatideGIP + GLP-1Dual incretin agonist
RetatrutideGIP + GLP-1 + glucagonTriple agonist

Semaglutide (GLP-1)

Semaglutide is a long-acting analogue of glucagon-like peptide-1 (GLP-1) that activates the GLP-1 receptor. It is the most established of the three and is widely prescribed in regulated markets. In a research context, it serves as a reference for a single-receptor incretin arm, useful when the experimental question is specifically about GLP-1 signalling without contribution from GIP or glucagon.

Tirzepatide (GIP / GLP-1)

Tirzepatide adds activity at the glucose-dependent insulinotropic polypeptide (GIP) receptor to GLP-1, making it a dual incretin agonist. Including GIP activity is the key distinction from semaglutide. Research programs that want to compare a single- versus dual-incretin mechanism often run semaglutide and tirzepatide as separate arms. ChainPep supplies tirzepatide reference material for these in-vitro comparisons.

Retatrutide (GIP / GLP-1 / glucagon)

Retatrutide extends the pattern to a third receptor, adding glucagon receptor agonism to GIP and GLP-1. Glucagon-related signalling is the element absent from the other two. It is the reference compound of choice when the study question explicitly involves the glucagon pathway alongside the two incretin receptors. See the retatrutide product page for current specifications and the dedicated retatrutide research overview.

What the evidence does and does not establish

Choosing for a research program

  1. Define the receptor pathway the experiment is testing.
  2. Match the compound to the pathway: GLP-1 → semaglutide; GIP+GLP-1 → tirzepatide; GIP+GLP-1+glucagon → retatrutide.
  3. Verify each lot's identity and purity against its HPLC and ESI-MS records before use (see how to read a peptide COA).
  4. Confirm handling and storage with the reconstitution guide.

All three compounds are available in the Weight Loss research compounds category as documented lyophilized reference material, with lot records accessible from each product page.

For in-vitro laboratory research use only. This material is not a drug, food, cosmetic or supplement and has not been evaluated by any regulatory authority. ChainPep does not provide usage, dosing or medical guidance; all handling must follow applicable laboratory safety regulations.

Frequently Asked Questions

What is the core molecular difference between the three?
Semaglutide is a long-acting GLP-1 receptor agonist; tirzepatide is a dual agonist at the GIP and GLP-1 receptors; retatrutide is a triple agonist that adds glucagon receptor activity to GIP and GLP-1. They differ in the number of incretin and related receptors they engage.
Are these approved drugs?
Semaglutide and tirzepatide are approved medicines under brand names in various jurisdictions, and retatrutide has been in late-stage clinical development. ChainPep does not sell these medicines; it supplies lyophilized reference compounds that are labeled for in-vitro laboratory research only, and they are not interchangeable with prescription products.
Which receptors does retatrutide target?
Retatrutide is described as a triple receptor agonist acting at GIP, GLP-1 and glucagon receptors. Tirzepatide targets GIP and GLP-1, while semaglutide targets GLP-1 alone.
Are these compounds safe to use for weight loss?
ChainPep provides no human-use, efficacy, or safety guidance. All three are research reference materials here; any human therapeutic use belongs to regulated, prescribed medicines and published clinical trials, not to research-vial supply. Animal-model findings must not be treated as confirmed human outcomes.
How should I choose between them for a research program?
Choose based on the receptor pathway under study, then confirm identity and purity from the HPLC and ESI-MS records. A GLP-1-only question points to semaglutide; a dual-incretin question to tirzepatide; a triple-pathway question including glucagon to retatrutide.